Investor's Business Daily on MSN
This biotech's LSD-based drug just treated depression. Now the stock is sky-high.
Definium Therapeutics skyrocketed Monday after its psychedelics-based depression treatment scored a "best-case" win in ...
People taking Definium Therapeutics' DT120 showed long-lasting reductions in their depression symptoms compared to a placebo, ...
Results for Definium Therapeutics psychedelic candidate for major depressive disorder “exceeded expectations,” according to ...
By Kamal Choudhury June 22 (Reuters) - Definium Therapeutics said a single dose of its LSD-based experimental pill ...
Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The ...
A clinical trial’s encouraging results won US Food and Drug Administration breakthrough therapy status for an LSD formulation to treat generalized anxiety disorder, Mind Medicine Inc. announced ...
A mid-stage study of a pharmaceutical version of the psychedelic LSD reported the drug might help alleviate anxiety symptoms for up to three months, advancing a potential treatment for the most common ...
Psychotropic drugs are all the rage now as a potential treatment of brain diseases. Examples are ketamine and psilocybin for depression and PTSD. More recently, a single dose of LSD was found to have ...
A new study suggests that lysergic acid diethylamide (LSD), also known as acid, could reduce anxiety. This marks the first-ever trial to evaluate the safety and efficacy of MM120 (a pharmaceutical ...
The latest LSD-based drug was used in a clinical trial to support patients with major depression in an initial step in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results